Our client, Saghmos Therapeutics is participating in a fireside chat at the @UBS Global Healthcare Conference tomorrow at 10:15 AM PT, 1:15 PM ET to discuss ST-62516 (trimetazidine) in development to reduce the risk of #cardiorenal complications post-PCI.

Join their CEO, Dr. Anna Kazanchyan, and Chief Regulatory Officer, Dr. Stephen Grant as they discuss their plans to move into a #Phase3 clinical study of ST-62516.

Read the press release for more information:#Cardiology #Renal #UBSConference
#cardiorenal